SCHEMBL1913541

SCHEMBL1913541

c1ccc2cc(-c3nc4ccccc4o3)ccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.62
RAB9A P51151 6/20 0.62
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
ATM Q13315 1/20 0.62
ALDH1A1 P00352 7/20 0.59
HPGD P15428 6/20 0.59
TP53 P04637 4/20 0.59
HSD17B10 Q99714 4/20 0.59
HCRTR1 O43613 3/20 0.59
MAPT P10636 3/20 0.59
PKM P14618 1/20 0.59
UTRN P46939 7/20 0.58
CYP1A2 P05177 1/20 0.58
AHR P35869 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
KDM4E B2RXH2 5/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
ESR1 P03372 2/20 0.57
ESR2 Q92731 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30727501 1.00 NPC1 (0.62) NPC1RAB9AMEN1KMT2AATM
SCHEMBL19846117 0.98 NPC1 (0.60) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2174585 0.96 NPC1 (0.66) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2220920 0.95 NPC1 (0.60) NPC1RAB9AMEN1KMT2AATM
SCHEMBL19846146 0.95 NPC1 (0.64) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2633271 0.95 NPC1 (0.64) NPC1RAB9AMEN1KMT2AATM
SCHEMBL19846119 0.93 NPC1 (0.63) NPC1RAB9AMEN1KMT2AATM
SCHEMBL19846148 0.90 NPC1 (0.59) NPC1RAB9AMEN1KMT2AATM
SCHEMBL25796476 0.90 NPC1 (0.59) NPC1RAB9AMEN1KMT2AATM
SCHEMBL13067477 0.89 NPC1 (0.62) NPC1RAB9AMEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111454387-B Curable composition, storage container, two-dimensional or three-dimensional image forming apparatus and method 株式会社理光 2022-10-18 CN claimed
CN-111454387-A Curable composition, storage container, two-dimensional or three-dimensional image forming apparatus and method 株式会社理光 2020-07-28 CN claimed
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy SUMMIT (OXFORD) LIMITED (GB) 2011-08-11 US claimed
WO-2005010081-A1 AROMATIC MONOMER-AND CONJUGATED POLYMER-METAL COMPLEXES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-02-03 WO claimed
US-20050014023-A1 Aromatic monomer- and conjugated polymer-metal complexes SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-01-20 US claimed
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-11-09 US disclosed
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-11-09 US disclosed
CN-111454387-B Curable composition, storage container, two-dimensional or three-dimensional image forming apparatus and method 株式会社理光 2022-10-18 CN disclosed
US-20220209132-A1 HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME Changchun Hyperions Technology Co., Ltd. (CN) 2022-06-30 US disclosed
EP-3227099-B1 PROCESS FOR PRODUCING TYRES PROVIDED WITH AUXILIARY COMPONENTS AND TYRE HAVING AN AUXILIARY COMPONENT PIRELLI (IT) 2020-11-18 EP disclosed
CN-111454387-A Curable composition, storage container, two-dimensional or three-dimensional image forming apparatus and method 株式会社理光 2020-07-28 CN disclosed
US-20200227644-A1 ORGANIC LIGHT-EMITTING DIODE OPERABLE AT LOW VOLTAGE WITH HIGH EFFICIENCY AND LONG LIFETIME SFC CO., LTD. (KR) 2020-07-16 US disclosed
WO-2005010081-A1 AROMATIC MONOMER-AND CONJUGATED POLYMER-METAL COMPLEXES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-02-03 WO disclosed
US-20050014023-A1 Aromatic monomer- and conjugated polymer-metal complexes SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-01-20 US disclosed
US-6808803-B1 STRUCTURE WITH SUBSTRATE, MONOMOLECULAR LAYER OF POLYCYCLIC AROMATIC COMPOUND HAVING DEFINED AXIS ORIENTED NORMAL TO PLANE OF MONOLAYER AND COVALENTLY ATTACHED AT ONE AXIAL END TO SUBSTRATE, SECOND LAYER WITH COMPOUND ATTACHED TO FIRST LAYER YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-10-26 US disclosed
US-20040202875-A1 STRUCTURE WITH SUBSTRATE, MONOMOLECULAR LAYER OF POLYCYCLIC AROMATIC COMPOUND HAVING DEFINED AXIS ORIENTED NORMAL TO PLANE OF MONOLAYER AND COVALENTLY ATTACHED AT ONE AXIAL END TO SUBSTRATE, SECOND LAYER WITH COMPOUND ATTACHED TO FIRST LAYER YISSUM RES & DEV CO OF HEBREW UNIV OF JERUSALEM (IL) 2004-10-14 US disclosed
US-6783849-B2 REACTING SUBSTRATE HAVING A SURFACE-EXPOSED MONOLAYER WITH A BIFUNCTIONAL REAGENT THAT REACTS WITH EXPOSED REACTIVE GROUP, PRODUCING COUPLING LAYER HAVING EXPOSED REACTIVE GROUP WITH WHICH REACTIVE GROUP OF SELECTED COMPOUND CAN REACT YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-08-31 US disclosed
US-20030040627-A1 Luminescent organometallic compound and light emitting device SANYO ELECTRIC CO., LTD. (JP) 2003-02-27 US disclosed
EP-0284395-A2 Novel glycerol derivative and anti-hypertensive agent NIPPON CHEMIPHAR CO., LTD. (JP) 1988-09-28 EP disclosed
EP-0275937-A2 Carpet adhesive Henkel Kommanditgesellschaft auf Aktien (DE) 1988-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF AHR, ORAI3, WNT3 NPC1 2396/4885RAB9A 3127/4885MEN1 2016/4885
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy PYGM, CPT1B, GYS1 NPC1 2477/4885RAB9A 3748/4885MEN1 3365/4885
US-20030040627-A1 Luminescent organometallic compound and light emitting device IK, CRY1, LBR NPC1 3891/4885RAB9A 1604/4885MEN1 176/4885
US-20220209132-A1 HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME EML4, STOM, GJB2 NPC1 3939/4885RAB9A 1754/4885MEN1 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.